Venous sinus thrombosis, more formally called cerebral venous sinus thrombosis (CVST), is a blood clot that forms in the large drainage channels of the brain. Unlike the arterial strokes most people think of, this type blocks the veins carrying blood out of the skull, causing a backup of pressure that can lead to brain swelling, bleeding, or infarction. It accounts for a small fraction of all strokes but disproportionately strikes younger adults and women, and its symptoms are notoriously easy to mistake for other conditions.
How Common Is It
CVST is rare compared with arterial stroke, but less rare than doctors once thought. A population-based study and meta-analysis covering British Columbia from 2000 to 2017 found an overall annual incidence of about 9 cases per million people, with women making up roughly 55 percent of cases and the average age sitting around 51.1PubMed. Incidence of Cerebral Venous Thrombosis: A Population-Based Study, Systematic Review, and Meta-Analysis A U.S. study that pulled data from a large insurance claims database found a somewhat higher overall rate of about 23 cases per million person-years, with the highest rates in men over 65 and women between 18 and 29.2JAMA Internal Medicine. Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination And a recent analysis of nearly 100 million U.S. emergency department visits between 2021 and 2023 identified CVST in about 43 out of every million encounters, with women representing roughly 61 percent of cases and the bulk of diagnoses falling between ages 25 and 64.3PubMed Central. Epidemiology of Cerebral Venous Sinus Thrombosis: 2021-2023
The numbers vary depending on how researchers look for cases, which is part of the story. Better imaging and greater clinical awareness have pushed incidence estimates upward over the past two decades. CVST was once considered exceedingly rare, but many milder cases were simply being missed.
Risk Factors
Most people who develop CVST have at least one identifiable risk factor, and many have more than one stacked on top of each other. The major categories include hormonal factors, inherited clotting disorders, infections, pregnancy and the postpartum period, cancer, and inflammatory diseases.
Hormonal contraceptives are probably the most discussed risk factor in younger women. Multiple studies have confirmed that combined oral contraceptives raise the odds of CVST, and the risk climbs sharply when a woman also carries an inherited clotting abnormality such as factor V Leiden or the prothrombin gene mutation.4PubMed. Hormonal contraceptives as a risk factor for cerebral venous and sinus thrombosis A recent case-control study put numbers on that interaction: women who both used combined hormonal contraceptives and had a thrombophilia had roughly 68-fold higher odds of developing a cerebral vein clot compared with women who had neither risk factor.5PubMed. The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study That multiplicative effect matters because many women are never tested for clotting disorders before starting the pill.
COVID-19 vaccines based on adenoviral vectors briefly pushed CVST into headline news. The condition known as vaccine-induced immune thrombotic thrombocytopenia, or VITT, involved an immune reaction that produced antibodies against a protein on platelets, driving both clotting and low platelet counts simultaneously.6PubMed Central. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources The mechanism turned out to hinge on the specific type of antibody produced: patients whose antibodies could activate platelets on their own, without needing extra protein present, were far more likely to develop CVST than those with a different antibody pattern.7PubMed. Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia VITT was genuinely rare, but it reshaped how many countries deployed those vaccines and deepened researchers’ understanding of immune-mediated clotting.
What It Feels Like
The classic textbook presentation of CVST is a headache that does not fit neatly into any familiar headache pattern, but in reality the symptoms are all over the map. A study examining headache characteristics in confirmed cases found that onset was acute in about half of patients, subacute in another 43 percent, and occasionally thunderclap or chronic. The headache was felt across the whole head in about a third of people and was located in the front in another quarter, with a throbbing quality being most common.8PubMed Central. Headache Patterns in Cerebral Venous Sinus Thrombosis On average, people had been living with the headache for nearly two weeks before diagnosis. That lag is telling: these headaches don’t always scream “emergency.”
Beyond headache, symptoms depend on where the clot sits and how much brain tissue is affected. Some people develop weakness on one side, vision changes, difficulty speaking, or confusion. Seizures are a particularly common feature of CVST, far more so than in arterial stroke. Reports of seizure rates in the acute phase range widely, from under 10 percent in some series to over 40 percent in others.9PubMed Central. Seizure in cerebral venous and sinus thrombosis Younger age, clots involving the veins near the brain surface, and the presence of bleeding in the brain tissue all increase the likelihood of seizures at presentation.10PubMed. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis Involvement of the frontal lobe in particular was independently associated with a tenfold increase in the odds of seizure in one analysis.11Journal of Epilepsy Research. Predictors of Presenting Seizures in Acute Cerebral Vein and Dural Sinus Thrombosis
The wide symptom range is exactly what makes diagnosis tricky. A young woman presenting with a severe new headache and seizure will trigger consideration of CVST fairly quickly. A middle-aged man with a gradually worsening headache and no other neurological findings might get worked up for migraines or sinusitis before anyone orders the right scan.
How It Gets Diagnosed
Diagnosis rests on imaging. The American Heart Association’s scientific statement on CVST lists MRI with MR venography and CT with CT venography as the primary diagnostic tools.12PubMed. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association A standard unenhanced CT scan of the head can sometimes show a bright (hyperdense) clot in a sinus or detect swelling from venous congestion, and CT venography with contrast adds detailed views of the venous system to confirm blockages.13PubMed. Cerebral venous thrombosis and multidetector CT angiography: tips and tricks
MRI offers some advantages, particularly a technique called susceptibility-weighted imaging. This sequence is sensitive to the magnetic properties of blood breakdown products inside a clot and has been shown to detect clot in sinuses and veins with around 90 percent sensitivity in the first three days, considerably higher than standard MRI sequences during that same window.14PubMed. MRI of clot in cerebral venous thrombosis: high diagnostic value of susceptibility-weighted images That sensitivity holds up well over the first week, making it especially useful in the acute phase when other sequences may miss a fresh clot. Susceptibility-weighted imaging is also better at catching clots limited to small cortical veins, which can be invisible on standard venography.
Anatomical Traps That Mimic Thrombosis
One underappreciated challenge in diagnosis is that some people are simply born with sinuses that are underdeveloped or absent on one side. If a radiologist is not alert to these normal variants, a small or missing sinus can look exactly like one that is blocked by clot. A study from Nepal observed that knowledge of sinus aplasia and hypoplasia is critical because they can be mistaken for partial or complete occlusion.15PubMed Central. Dural Venous Sinus Variations Observed in Magnetic Resonance Venography at a Tertiary Care Hospital: An Observational Study An older anatomical review went further, arguing that the so-called “delta sign” on CT, long considered a hallmark of sinus thrombosis, can sometimes be nothing more than the anatomical result of a naturally absent or underdeveloped sinus.16Acta Anatomica. Cerebral Venous Sinuses: Anatomical Variants or Thrombosis?
This means that low-quality or ambiguous imaging results can lead to overdiagnosis, where people are told they have a brain clot they never actually had, potentially starting them on blood thinners they do not need. When findings are borderline, many centers will repeat the study with a different technique or compare both sides of the venous system to look for asymmetry that falls within normal variation.17Indian Journal of Medical Sciences. Variations in the cerebral venous anatomy and pitfalls in the diagnosis of cerebral venous sinus thrombosis: Low field MR experience
Treatment in the Acute Phase
Anticoagulation, meaning blood-thinning medication, is the backbone of treatment. This can feel counterintuitive because many patients with CVST already have some bleeding in the brain at the time of diagnosis, and the instinct might be to avoid thinning the blood further. But the evidence supports anticoagulation even in those patients. A network meta-analysis found that both low-molecular-weight heparin and unfractionated heparin were superior to placebo in patients with CVST accompanied by hemorrhagic stroke, and that low-molecular-weight heparin appeared more effective than unfractionated heparin in that subgroup.18PubMed Central. Efficacy and risks of anticoagulation for cerebral venous thrombosis A separate systematic review and meta-analysis showed that anticoagulation was associated with a trend toward lower mortality and disability, and that new brain hemorrhages were actually more common among patients on placebo than on treatment.19PubMed. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis
When patients deteriorate despite anticoagulation, interventional approaches come into play. Endovascular procedures, where a catheter is threaded into the affected sinus to physically break up or dissolve the clot, have been used as a salvage strategy in severe cases with heavy clot burden.20Scientific Reports. Endovascular Mechanical Thrombectomy and On-Site Chemical Thrombolysis for Severe Cerebral Venous Sinus Thrombosis In truly life-threatening situations where coma has set in and the brain is herniating, open surgical thrombectomy combined with removal of part of the skull to relieve pressure has been described as a last resort that can still produce favorable outcomes.21PubMed. Surgical Thrombectomy Combined with Bilateral Decompressive Craniectomy in a Life-Threatening Case of Coma from Cerebral Venous Sinus Thrombosis: Case Report and Literature Review
Long-Term Blood Thinners and Newer Options
After the acute phase, patients typically continue anticoagulation for months. The traditional choice has been a vitamin K antagonist like warfarin, which requires regular blood monitoring. Direct oral anticoagulants (DOACs), which do not require monitoring, have increasingly been used instead. A systematic review and meta-analysis comparing the two found that DOACs had comparable rates of recurrent clotting, major bleeding, brain hemorrhage, death, and complete reopening of the blocked vein.22PubMed. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis A large international observational study published in The Lancet Neurology reinforced that conclusion, finding nearly identical rates of the primary composite outcome (recurrent thrombosis, major bleeding, or death) in patients treated with DOACs compared with warfarin-type drugs.23The Lancet Neurology. Direct oral anticoagulants versus vitamin K antagonists in cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study
Randomized trial data are still being gathered. An international phase IV study protocol has been published specifically to compare DOACs with vitamin K antagonists in a more rigorous design.24PubMed Central. Direct oral anticoagulants for the treatment of cerebral venous thrombosis – a protocol of an international phase IV study For now, the totality of evidence from observational data and meta-analyses makes DOACs a reasonable choice, but practice still varies between centers and individual doctors.
Outcomes and Life Afterward
The good news is that most people survive CVST, and a majority recover well enough to function independently. A prospective study of 82 patients found that about 82 percent recovered completely within a year, though roughly 5 percent experienced new clotting events and 10 percent had seizures during follow-up.25Cerebrovascular Diseases. Long-Term Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the VENOPORT Study But that rosy top-line number hides subtler problems. An older but often-cited study that tested patients’ thinking abilities at least a year after diagnosis found that about 35 percent had measurable cognitive difficulties, 40 percent reported symptoms that restricted their daily lives, and 40 percent could not return to their previous level of work.26PubMed. Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis
Depression is another underrecognized aftereffect. In one cohort assessed after discharge, 30 out of the total group met criteria for depression, and impairment in psychosocial functioning appeared even among patients whose physical recovery scores looked good.27PubMed Central. Depression and Quality of Life after Cerebral Venous Sinus Thrombosis This disconnect between functional independence and quality of life is something survivors and their families should be prepared for. A person might walk and talk normally but struggle with concentration, fatigue, and mood in ways that are invisible to outsiders.
Pregnancy After CVST
Because CVST strikes many women during their reproductive years, the question of whether it is safe to become pregnant afterward comes up frequently. The reassuring answer is that recurrence during a subsequent pregnancy appears to be uncommon when prophylactic blood thinners are used. The ISCVT-2 PREGNANCY study followed 47 women through 82 new pregnancies after a prior CVST, and only three venous clotting events occurred, including one recurrent CVST. Most of these women received some form of blood-thinner prophylaxis during pregnancy or the postpartum period.28PubMed. Safety of Pregnancy After Cerebral Venous Thrombosis: Results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY Study
A separate analysis of 63 pregnant women with prior CVST on low-molecular-weight heparin found a similarly low recurrence rate of about 3 percent and no bleeding episodes, but noted a higher-than-expected rate of obstetrical complications including miscarriage and late pregnancy problems, regardless of whether the woman carried a clotting disorder.29PubMed. Pregnancy after cerebral venous thrombosis The takeaway is that pregnancy is not off the table, but it warrants close collaboration between a hematologist, neurologist, and obstetrician throughout.
CVST in Children and Newborns
CVST is not only an adult condition. A large Canadian registry found an incidence of about 0.67 cases per 100,000 children per year, with newborns being the most commonly affected age group. Seizures occurred in 58 percent of pediatric cases, and risk factors included head and neck problems, acute systemic illnesses, chronic diseases, and inherited clotting tendencies. About 38 percent of the children had persistent neurological problems, and 8 percent died.30PubMed. Cerebral sinovenous thrombosis in children
In newborns specifically, the picture tends to be more severe. A prospective study of 90 neonates with CVST found that outcomes were normal in only 39 percent, while 61 percent had abnormal outcomes including five deaths. Among the survivors assessed with formal testing, nearly half had moderate-to-severe deficits spanning movement, language, and cognition.31PubMed Central. A Prospective Outcome Study of Neonatal Cerebral Sinovenous Thrombosis Preterm infants present additional challenges; seizures and abnormal examination findings are the most common presenting features, and brain injury in premature babies tends to cluster around the deep white matter rather than near the cortex as in older children.32PubMed. Cerebral Venous Sinus Thrombosis in Preterm Infants Anticoagulation was used in most preterm cases and did not appear to worsen existing brain bleeding, though the numbers are small and this remains an area where clinicians weigh risk and benefit case by case.
Infections and the Cavernous Sinus
One particular subtype deserves its own mention. Septic cavernous sinus thrombosis occurs when an infection, often originating in the sinuses, ears, or face, spreads to the cavernous sinus and seeds a clot loaded with bacteria. Before antibiotics existed, this condition was considered essentially fatal. Antibiotic treatment has dramatically reduced the death rate, but even now most patients who survive are left with neurological aftereffects, highlighting how aggressive the infection can be and how much early recognition matters.33PubMed Central. Septic cavernous sinus thrombosis: A review
Dural Arteriovenous Fistulas as a Late Complication
An uncommon but clinically important sequel to CVST is the development of dural arteriovenous fistulas, which are abnormal connections between arteries and veins within the tough membrane surrounding the brain. In a study of 55 patients who had both conditions, signs of recent or past sinus thrombosis were visible at the time the fistula was first diagnosed in 60 percent of cases, while in another third the thrombosis developed after the fistula was found. In the vast majority, the clot and the fistula occupied the same sinus, pointing to a direct anatomical relationship.34American Journal of Neuroradiology. Association between Dural AVFs and Cerebral Venous Thrombosis The exact cause-and-effect relationship remains debated. It may be that chronic thrombosis damages the sinus wall and stimulates new vessel growth, or that the fistula’s turbulent flow promotes clotting, or both. Either way, patients who have had CVST sometimes need follow-up imaging to check for this complication, especially if new symptoms develop.35PubMed Central. Clinical characteristics and outcome of dural arteriovenous fistulas secondary to cerebral venous sinus thrombosis: a primary or secondary event?
A Brief Historical Note
The condition was first described in 1825 by the French physician Ribes, who reported a patient with severe headache and epilepsy caused by clots in the superior sagittal and lateral sinuses. Three years later, John Abercrombie, physician to King George IV of England, published the first case linked to childbirth: a 24-year-old woman who developed headaches and seizures two weeks after delivery and died of prolonged seizure activity. Autopsy revealed thrombosis of the superior sagittal sinus and cortical veins.36Journal of Thrombosis and Haemostasis. Cerebral venous thrombosis For well over a century afterward, CVST was considered uniformly devastating and nearly always fatal. It was only with the advent of modern imaging and anticoagulation that the condition went from a diagnosis made at autopsy to one made in the emergency room, with most patients surviving to recovery.